Hepatitis C - New drugs and treatment prospects.

@article{Zajac2019HepatitisC,
  title={Hepatitis C - New drugs and treatment prospects.},
  author={M. Zajac and I. Muszalska and A. Sobczak and Adrianna Dadej and Szymon Tomczak and A. Jelińska},
  journal={European journal of medicinal chemistry},
  year={2019},
  volume={165},
  pages={
          225-249
        }
}
Hepatitis C virus (HCV) affects approx. 3% of the world's population and accounts for ca 300 000 deaths per year. 80% of individuals with HCV develop chronic symptoms which, when untreated, may cause cirrhosis (27%) or hepatocellular carcinoma (25%). The hepatitis C virus is a (+)ssRNA enveloped virus of the family Flaviviridae. Seven major HCV genotypes and their subtypes (a, b) have been identified. In the 1990s, interferons alpha-2 were used in the treatment of HCV and in the next decade HCV… Expand
Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C
TLDR
This review focuses on the pharmacokinetics, efficacy, tolerability and safety profile of DCV-TRIO, a twice-daily fixed-dose combination of daclatasvir, asunaprevir and beclabuvir approved in Japan for the treatment of genotype 1 HCV infection. Expand
Evolution and Revolution of Hepatitis C Management: From Non-A, Non-B Hepatitis Toward Global Elimination
TLDR
Better understanding of HCV structure, enzymes, and lifecycle led to the discovery of direct-acting antivirals and IFN-free era, and successful HCV therapy created a rare possibility of global disease eradication. Expand
Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review
TLDR
The aim of the present narrative review was to provide an overview of the impact of baseline RASs in patients treated with the latest-generation DAAs and to analyze the efficacy of the available retreatment strategies in those who have failed these regimens. Expand
Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment.
TLDR
Results suggest that 7e as a CypA inhibitor could be used as an alternative anti-HCV agent in combinational therapy in the future. Expand
The Prevalence and Impact of Hepatic Steatosis on Response to Direct-Acting Antiviral Therapy in HIV–HCV Coinfection
TLDR
Hematic steatosis is common in HIV–HCV coinfection, correlates with obesity and the metabolic syndrome and does not impact SVR. Expand
In silico design and analysis of NS4B inhibitors against hepatitis C virus.
TLDR
This work explores the relationships between the molecular structures of biologically tested NS4B inhibitors and their corresponding inhibitory activities to assist the design of novel and potent NS4 B inhibitors and believes that this strategy could help in the design and screening of potential inhibitors in drug discovery. Expand
Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma
Simple Summary Hepatocellular carcinoma pathogenesis is dependent on a chronic inflammation caused by several factors, including hepatotropic viruses, such as HCV and HBV. This chronic inflammationExpand
Fludarabine Inhibits Infection of Zika Virus, SFTS Phlebovirus, and Enterovirus A71
TLDR
Fludarabine, a fluorinated purine analogue, effectively inhibited infection of RNA viruses, including Zika virus, Severe fever with thrombocytopenia syndrome virus, and Enterov virus, with all IC50 values below 1 μM in Vero, BHK21, U251 MG, and HMC3 cells. Expand
RETRACTED ARTICLE: Thiophen urea derivatives as a new class of hepatitis C virus entry inhibitors
TLDR
The docking results suggested the potential interaction of J2H-1701 with the HCV E2 glycoprotein and suggest that J 2H- 1701 can be a potential candidate drug for the development of HCV entry inhibitors. Expand
Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice
TLDR
The present data suggest that the two entirely structurally different CypIs—CRV431 and NV556—derived from unrelated natural products, represent attractive partners to current direct-acting agent (DAA) regimens for the treatment of hepatitis C and liver diseases. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 88 REFERENCES
Progress in the development of vaccines for hepatitis C virus infection.
TLDR
Progress in the development of preventive and therapeutic vaccines against the HCV is reviewed in the context of peptide vaccines, recombinant protein vaccines, HCV-like particle, DNA vaccines and viral vectors expressing HCV genes. Expand
A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir.
TLDR
Preclinical and clinical data regarding sofosbuvir, a uridine nucleotide analogue inhibitor of HCV NS5 B polymerase that is effective against HCV genotypes 1,2, 3,4 and 6, suggest that it represents a very promising option in the treatment of chronic hepatitis C. Expand
Direct antiviral agents (DAAs) ‐ A new age in the treatment of hepatitis C virus infection
TLDR
DAA combination therapy has the potential to obtain global control over hepatitis C and an overview over currently approved regimens and outlines their use in clinical practice is provided. Expand
The role of resistance in HCV treatment.
TLDR
The parameters that determine DAA resistance as well as the clinical implications of resistance testing are reviewed, and the most recent literature and conference data on resistance profiles of DAAs in clinical development and future strategies to avoid the emergence of viral resistance are discussed. Expand
Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential
  • C. Stedman
  • Medicine
  • Therapeutic advances in gastroenterology
  • 2014
TLDR
Sofosbuvir has a pan-genotypic effect on HCV, although viral genotype-specific differences in sustained virological response (SVR) have emerged in phase III clinical trials. Expand
Daclatasvir: potential role in hepatitis C
  • Choongho Lee
  • Medicine
  • Drug design, development and therapy
  • 2013
TLDR
In this review, a variety of preclinical as well as clinical proof-of-concept studies of daclatasvir, including the studies of its discovery, mechanism of action, viral resistance, and host polymorphism profiles are reviewed. Expand
A review of the current anti-HCV therapy: Are we finally ready for interferon-free regimens
TLDR
The description of current regimens in the treatment of hepatitis C and the much eagerly awaited future all new oral anti-hepatitis C regimen, which can potentially eliminate the use of painful injections of interferon are described. Expand
Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance.
TLDR
To design robust inhibitors that retain potency to drug-resistant NS3/4A protease variants, inhibitors should combine P1-P3 macrocycles with flexible P2 moieties that optimally contact with the invariable catalytic triad of this enzyme. Expand
Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.
TLDR
This review will focus on inhibitors of the HCV-encoded NS5B RNA-dependent RNA polymerase (NS5B RdRp) which is essential for viral replication and has been recognized as a prime target for therapeutic intervention. Expand
Anti-hepatitis C virus drugs in development.
TLDR
New reagents that target specific elements of viral replication, including viral proteins and host factors required for replication, should lead to highly effective, well-tolerated, and likely interferon-sparing therapies in the next several years. Expand
...
1
2
3
4
5
...